CI

At a glance

ClinicalIndex Comparison Record
Phase 1Unknown· 20 target
Drug / intervention
Individualized neoantigen peptides vaccinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04397926
NCT04397926Phase 1Unknown
CompareCT.gov

Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer

Sun Yat-sen University·interventional·Posted May 21, 2020·Updated Jun 11, 2020

In Brief

A Phase 1 clinical trial evaluating Individualized neoantigen peptides vaccine for Non Small Cell Lung Cancer. Targeting 20 participants across 1 site.

Detailed Summary

Neoantigen vaccine is a new field of research in tumor immunotherapy, and some studies have been conducted with success on Melanoma and glioblastoma. Nearly 80% of lung cancers are diagnosed in an advanced stage (IIIB, and IV) and EGFR mutant non-small cell lung cancer will be resistant after targeted drug treatment. Neoantigen vaccine is a new treatment method for lung cancer, especially for patients with drug resistance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer
CountriesChina
CollaboratorsTianjin Hengjia Biotechnology Development co., LTD

Timeline

Phase 1UnknownOverdue
202120222023202420252026
First PostedMay 21, 2020
Enrollment StartMay 30, 2020
Primary CompletionMay 30, 2022
Study CompletionDec 30, 2022
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 6.1 years ago

Interventions

Individualized neoantigen peptides vaccinedrug

Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks